NASDAQ:HROW

Harrow Health (HROW) Stock Forecast, Price & News

$19.56

+0.05 (+0.26%)

(As of 06/2/2023 ET)

Compare

Today's Range: $19.08
▼
$19.71
50-Day Range: $18.86
▼
$28.08
52-Week Range: $6.00
▼
$28.25

Volume: 220,342 shs
Average Volume: 626,787 shs
Market Capitalization: $589.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.47

Harrow Health MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 55.8% Upside
$30.47 Price Target
Short Interest: Bearish
7.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 1,450.00%
From $0.06 to $0.93 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

364th out of 983 stocks

Pharmaceutical Preparations Industry

173rd out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Harrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.47, Harrow Health has a forecasted upside of 55.8% from its current price of $19.56.
Amount of Analyst Coverage
Harrow Health has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.34% of the outstanding shares of Harrow Health have been sold short.
Short Interest Ratio / Days to Cover
Harrow Health has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Harrow Health has recently increased by 1.38%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Harrow Health does not currently pay a dividend.
Dividend Growth
Harrow Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HROW.

2.6

News and Social Media Coverage

News Sentiment
Harrow Health has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Harrow Health this week, compared to 3 articles on an average week.
Search Interest
Only 33 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
MarketBeat Follows
7 people have added Harrow Health to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harrow Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.26% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.47% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Harrow Health are expected to grow by 1,450.00% in the coming year, from $0.06 to $0.93 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harrow Health is -30.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harrow Health is -30.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harrow Health has a P/B Ratio of 27.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Harrow Health (NASDAQ:HROW) Stock

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Stock News Headlines

May 27, 2023 | americanbankingnews.com

Harrow Health (NASDAQ:HROW) Shares Down 9%

May 17, 2023 | americanbankingnews.com

Harrow Health (NASDAQ:HROW) Trading Down 5%

June 4, 2023 | Altimetry (Ad)

Surprising "Twist" Hands Biden Landslide Re-election?

This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.

May 17, 2023 | finance.yahoo.com

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023

May 17, 2023 | americanbankingnews.com

B. Riley Weighs in on Harrow Health, Inc.'s Q2 2023 Earnings (NASDAQ:HROW)

May 16, 2023 | finance.yahoo.com

Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call Transcript

May 13, 2023 | americanbankingnews.com

Harrow Health (NASDAQ:HROW) Given New $32.40 Price Target at LADENBURG THALM/SH SH

May 12, 2023 | markets.businessinsider.com

Lake Street Keeps Their Buy Rating on Harrow Health (HROW)

June 4, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 12, 2023 | msn.com

Harrow Health falls 23% despite Q1 revenue beat

May 12, 2023 | finance.yahoo.com

Why Shares of Harrow Health Are Slumping Friday

May 12, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Harrow Health (HROW)

May 12, 2023 | americanbankingnews.com

Harrow Health (NASDAQ:HROW) Hits New 52-Week High at $28.25

May 11, 2023 | seekingalpha.com

Harrow Health, Inc. (HROW) Q1 2023 Earnings Call Transcript

May 11, 2023 | msn.com

Recap: Harrow Health Q1 Earnings

May 10, 2023 | msn.com

Earnings Preview For Harrow Health

May 9, 2023 | americanbankingnews.com

Harrow Health (HROW) to Release Quarterly Earnings on Thursday

May 9, 2023 | americanbankingnews.com

Harrow Health, Inc. Expected to Earn Q1 2023 Earnings of ($0.06) Per Share (NASDAQ:HROW)

May 8, 2023 | msn.com

Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?

May 5, 2023 | americanbankingnews.com

Harrow Health's (HROW) Buy Rating Reaffirmed at B. Riley

May 4, 2023 | finance.yahoo.com

Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

May 4, 2023 | americanbankingnews.com

SCYNEXIS (NASDAQ:SCYX) versus Harrow Health (NASDAQ:HROW) Head to Head Analysis

May 3, 2023 | americanbankingnews.com

Harrow Health, Inc. (NASDAQ:HROW) Short Interest Update

May 1, 2023 | finance.yahoo.com

Here's Why Momentum in Harrow (HROW) Should Keep going

April 28, 2023 | finance.yahoo.com

Zacks.com featured highlights Harrow Health and Disc Medicine Opco

April 27, 2023 | finance.yahoo.com

2 Stocks in Focus as Analysts Initiate Coverage

April 24, 2023 | nasdaq.com

Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day

See More Headlines

HROW Price History

30 days | 90 days | 365 days | Advanced Chart

HROW Company Calendar

Last Earnings: 3/23/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HROW
CUSIP: N/A
CIK: 1360214
Web: www.harrowinc.com
Phone: (615) 733-4730
Fax: 858-345-1745
Employees: 182
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $30.47
High Stock Price Forecast: $37.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +55.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 326.00
P/E Growth: N/A
Net Income: $-14,090,000.00
Net Margins: -19.76%
Pretax Margin: -19.99%
Return on Equity: -1.57%
Return on Assets: -0.15%

Debt

Debt-to-Equity Ratio: 7.84
Current Ratio: 2.92
Quick Ratio: 2.41

Sales & Book Value

Annual Sales: $88.60 million
Price / Sales: 6.65
Cash Flow: $0.22 per share
Price / Cash Flow: 88.23
Book Value: $0.71 per share
Price / Book: 27.55

Miscellaneous

Outstanding Shares: 30,120,000
Free Float: 25,827,000
Market Cap: $589.15 million
Optionable: Optionable
Beta: 0.20

Key Executives

Mr. Mark L. Baum J.D. (Age 49)
CEO & Chairman
Comp: $1.07M

Mr. Andrew R. Boll C.F.A. (Age 40)
C.M.A., CFA, CMA, CFO & Corp. Sec.
Comp: $716.73k

Dr. Robert J. Kammer D.D.S. (Age 73)
Special Advisor
Comp: $91.88k

Mr. John P. Saharek MBA (Age 62)
Chief Commercial Officer
Comp: $621.92k

Jamie Webb
Director of Communications & Investor Relations

Dr. Dennis E Saadeh Pharm.D.
Chief of Formulation Strategy

Mr. Andrew Livingston
Chief Innovation Officer

Ms. Kim Barratt
Chief Talent Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HROW Stock - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares.
View HROW analyst ratings or view top-rated stocks.
What is Harrow Health's stock price forecast for 2023?: 2 brokers have issued twelve-month price targets for Harrow Health's stock. Their HROW share price forecasts range from $22.00 to $37.00. On average, they expect the company's share price to reach $30.47 in the next year. This suggests a possible upside of 55.8% from the stock's current price.
View analysts price targets for HROW or view top-rated stocks among Wall Street analysts.
How have HROW shares performed in 2023?: Harrow Health's stock was trading at $14.76 at the start of the year. Since then, HROW stock has increased by 32.5% and is now trading at $19.56.
View the best growth stocks for 2023 here.
When is Harrow Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our HROW earnings forecast.
How were Harrow Health's earnings last quarter?: Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings data on Thursday, March, 23rd. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.22. The firm had revenue of $20.33 million for the quarter, compared to analyst estimates of $23.26 million. Harrow Health had a negative net margin of 19.76% and a negative trailing twelve-month return on equity of 1.57%.
What ETFs hold Harrow Health's stock?: ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS), Hartford Multifactor Small Cap ETF (ROSC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and
What guidance has Harrow Health issued on next quarter's earnings?: Harrow Health issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$143.00 million, compared to the consensus revenue estimate of $137.06 million.

What other stocks do shareholders of Harrow Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).
What is Harrow Health's stock symbol?: Harrow Health trades on the NASDAQ under the ticker symbol "HROW."
Who are Harrow Health's major shareholders?: Harrow Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Braidwell LP (4.82%), Private Capital Management LLC (3.87%), Portolan Capital Management LLC (3.56%), Renaissance Technologies LLC (3.20%), Assenagon Asset Management S.A. (2.68%) and BlackRock Inc. (1.65%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends.
How do I buy shares of Harrow Health?: Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Harrow Health's stock price today?: One share of HROW stock can currently be purchased for approximately $19.56.
How much money does Harrow Health make?: Harrow Health (NASDAQ:HROW) has a market capitalization of $589.15 million and generates $88.60 million in revenue each year. The company earns $-14,090,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.
How many employees does Harrow Health have?: The company employs 182 workers across the globe.
How can I contact Harrow Health?: Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745.

This page (NASDAQ:HROW) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial